Foghorn Therapeutics Inc.
FHTX
$4.88
-$0.18-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.42% | 7.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.42% | 7.89% | |||
| Cost of Revenue | 10.22% | -8.21% | |||
| Gross Profit | -8.02% | 16.76% | |||
| SG&A Expenses | 2.18% | -3.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.21% | -6.98% | |||
| Operating Income | -5.92% | 12.31% | |||
| Income Before Tax | -36.69% | 11.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -36.69% | 11.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -36.69% | 11.64% | |||
| EBIT | -5.92% | 12.31% | |||
| EBITDA | -6.49% | 12.83% | |||
| EPS Basic | -36.58% | 11.69% | |||
| Normalized Basic EPS | -9.61% | 11.69% | |||
| EPS Diluted | -36.58% | 11.69% | |||
| Normalized Diluted EPS | -9.61% | 11.69% | |||
| Average Basic Shares Outstanding | 0.06% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||